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Abstract 
The architectural design of dendrimers, multivalency, well-defined molecular weight and 
higher degree of branching differentiates them as unique and excellent nanocarriers in 
therapeutic applications such as drug delivery, gene transfection, tumor therapy, imaging and 
diagnostics. Nanoparticle drug-delivery systems are well known to increase the stability and 
selectivity of therapeutic agents. However immunogenicity, reticuloendothelial system uptake, 
drug leakage, cytotoxicity, hemolytic toxicity, poor aqueous solubility restrict the use of these 
drug delivery systems. These defects are overcame by surface engineering of the dendrimer 
molecule. 
 Drug molecule can be efficiently conjugated or encapsulated into the interior of the 
dendrimer or physically adsorbed onto the surface of the dendrimer. And therefore, desired 
properties of the drug delivery system to specific needs of the medicine and its therapeutic 
functions such as in anticancer therapies and diagnostic imaging has highlighted the advantage of 
these systems as newest class of macromolecular nano-scale delivery devices. The focus of this 
review is mainly on the work done in the usage of dendrimer nanoparticles as drug delivery 
vehicles and its development in recent years. 
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Introduction 
Many of the novel drugs discovered by the pharmaceutical industry today are 
hydrophobic compounds and have low solubility making difficult the delivery of these new 
drugs, also affect the delivery of many existing drugs .Since we have limited choices of delivery 
technologies and higher complexity in dissolution testing the ability to deliver these low 
solubility profile drugs through any novel systems is  gaining significance lately as most of these 
new drugs are based upon a  larger share of revenue within the pharmaceutical market by pioneer 
companies. 
Most of the poorly soluble drugs have instigated the growth of many drug delivery 
technologies through either mechanical or chemical modification of the outer part of drug 
molecule or by physically converting the macro molecular characteristics of drug particles. 
These mechanization processes include particle size reduction through spray drying and 
communition, drug dispersion in carriers, cyclodextrin mediated inclusion complexes and 
micellar solubilization [1-3]. But the employment of micelle mainly depends on their structure 
and stability; it is important to seek micelles with stable size and structure. Dendrimers with 
hydrophilic exterior and hydrophobic interior have shown to exhibit micelle like properties[4] 
and has been proven to be advantageous over conventional polymer micelles since their structure 
is maintained at all concentrations because the interior hydrophobic segments are covalently 
attached. 
The unique properties of Dendrimer such as its multivalency, immense branching, 
globular shape and controlled surface functionalities make them promising candidates for drug  
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delivery [5-8], magnetic resonance imaging [9-11] and as gene carriers [12-15] to the 
development of antivirals and anti-cancer drugs [16-19]. Dendrimers also provide path to various 
novel polymer structures that are possibly relevant to drug delivery applications besides 
contributing a multivalent backbone to attachment of the drug. 
Design and constitution    
Dendrimers are built from a series of branches around an inner core, providing products 
of different generations. They can be constructed from any core molecule and the branches 
similarly constructed from any bi-functional molecule. Certain general principles are being 
established [20] for preparing these novel systems as delivery vehicles which are listed as: i) 
dendrimer design can effectively influence pharmacokinetics; ii) neutral and negatively charged  
dendrimers are normally bio-compatible; iii)targeting components bound to surface of dendrimer 
can be used to specifically treat cancerous cells with over-expressed receptors; iv)targeting 
components can also be internalized into the empty space present between core and periphery, or 
bonded covalently to surface functional groups.  
The structure of dendrimer can be put into three parts: a) multivalent surface, with a high 
number of possible reactive sites; b) The ‘outer shell’ just beneath the surface having a well-
defined micro environment protected from outside by the dendrimer surface; c) The core, 
wherein higher generation dendrimers are protected from the surroundings, creating a smaller 
environment surrounded by the branches of dendrimers [21]. Thus, dendrimer as a host provides 
the best interior for encapsulation of the guest substances. The multivalent surfaces on a higher- 
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generation dendrimer can contain a very large number of functional groups. This makes the 
surface of the dendrimer and outer shell best for host–guest interactions. 
The stepwise synthesis of these novel systems with level of control yields molecules with 
unique molecular weight, high degree of branching, and with a number of well-defined 
peripheral groups which is not possible with many linear polymers and also these dendritic 
carriers provide the passive targeting of drugs to tumor sites. The unique properties of dendritic 
polymers over linear polymers make them interesting candidates for the development of 
anticancer drug delivery systems.  
In a dendrimer the branching units are termed as generation, initiating with the central 
branched core as generation 0 and increasing with each consecutive addition of branching units 
in which number of end groups rises exponentially with these additions and attain a more 
globular shape due to increase in diameter[22]. Researchers have studied the effect of solubility 
enhancement with dendrimer generation and most of them noted that increasing generation 
number resulted in increased solubility of a hydrophobe. But as compared to higher generations, 
dendrimers unto generation 3 have proved to be more biocompatible and less immunogenic. 
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FIGURE 1.Designs of various dendrimers. Top left: unimolecular micelle [23]; top right: 
polyaryl ether dendrimer [24]; bottom left: polylysine [25]; bottom middle: carbohydrate 
dendrimer [26]; bottom right: silicon based dendrimer [27]. 
Synthesis 
Two strategies have been into use for synthesis of dendrimers one process is known as 
divergent method invented by Tomalia and Newkome [28-30] which dendrimer can be grown 
from a central core towards outside and built out generation by generation. Nevertheless, the  
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high number of reactions which have to be performed on a single molecule (with many 
equivalent reaction ‘sites’), demands very effective transformations (yield=99+ %) to avoid 
defects. One good example is PAMAM (polyamidoamine) dendrimers and the other one is 
known as Frechet’s convergent method on which dendrimer can be grown from the periphery 
inwards, ending at the core [31], example polyaryl ether dendrimers. In this method only a small 
number of reactive sites are functionalized in each step, giving less number of possible side-
reactions in each step. Each synthesized generation of the dendrimer hence can be purified, 
although purification in the higher-generation dendrons becomes more massive, because of the 
increasing similarity between reactants and formed product. Anyhow, with proper purification 
after each step, dendrimers without any defects can be obtained. It is also possible to produce an 
interesting asymmetric dendrimer structures by joining two different segments of dendrimer in a 
strict fashion. 
 
 
FIGURE 2 -Schematic Dendrimer synthesis Top: Divergent strategy, Bottom: Convergent 
strategy [32] 
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Development of biodegradable dendrimers 
Apart from biocompatible and water soluble dendrimers, recently a few dendrimers have 
been designed to be biodegradable, and monomers that are products in metabolic pathways or 
intermediates in a chemical reaction have been included. For instance, many peptide based 
dendrimers like those based on polylysine (figure 3c) [33] with suitable peripheral changes [34] 
have been noted and have been developed as promising vaccines and antibacterial substances. 
Highly compatible PEO {poly (ethylene oxide)} has been lately prepared by Frechet et al [35] as 
a challenging and promising backbone for biological applications. They have also explored 
polyester dendrimers [36, 37] based on the monomer 2, 2-bis propionic acid (figure 3d) with 
PEO as substances for development of delivery systems for anticancer drugs. Grinstaff et al [82] 
also prepared polyester dendrimer based on glycerol, succinic acid (figure 3e), lactic acid and 
phenylalanine which have been successfully used in tissue engineering. Several other dendrimers 
such as triazines prepared by Simanek et al and their biological applications has been 
demonstrated [38]. 
Dendrimers as drug delivery vehicles and their pharmaceutical applications 
Controlled release to the desired target, biodistribution of drug and pharmacokinetics are 
the key factors which help in producing an ideal dendrimer and such ideally produced dendrimer 
should also exhibit low toxicity, drug-loading capacity and high aqueous solubility, favorable 
retention, specificity, appropriate bioavailability and biodistribution, biodegradability [39]. A 
drug is either covalently conjugated or non-covalently encapsulated inside the dendrimer to form 
macromolecular prodrugs, thereby used for drug delivery.  
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In order to obtain particular cellular treatment, drug carriers must be designed to direct 
the drug into the cell and one good example for cell specific dendritic drug vehicles is a 
dendrimer derivatized with folic acid (pteroyl-L-glutamic acid). Folic acid is an important 
substrate for uptake in cells by the folate receptor pathway. Since the folate receptor is over-
expressed in cancerous cells, these folic acid derivatized dendrimers are taken up by cancer cells 
as an alternative to normal cells, making these dendrimers well-suited for the cancer specific 
drug delivery of cytotoxic candidates[40,41]. 
Dendrimers as drug carriers into DNA      
Dendrimer mediated drug delivery has mainly been focused on the delivery of DNA 
drugs into the cell nucleus for gene or anti-sense therapy, and many reports have been published 
on the possible use of unmodified amino-terminated PPI or PAMAM dendrimers as non-viral 
gene transfer agents, improving the transfection of DNA into the cell nucleus. It has also been 
found that partially fragmented dendrimers are better suited for gene delivery than the complete 
dendrimers since they have a more flexible structure (fewer amide bonds) and form a more 
tightly packed complex with DNA, and a fragmentation step consisting of hydrolytic cleavage of 
the amide bonds is needed to enhance the transfection efficiency. As experiments suggests a few 
cationic, amino-terminated dendrimers which are partially covalently modified with drugs, can 
be used as extracellular ‘stickers’ in ‘extracellular matrix-targeted local drug delivery,’ giving a 
very high local concentration of the drug near the cellular surface[42]. However, this drug (gene) 
delivery technique is only appropriate if a particular drug or gene has to be introduced into a 
broad range of cells. 
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Figure 3.[31-38].Biocompatible dendrimers.(a) PAMAM dendrimer (b) Polyaryl ether 
dendrimer(c) Polylysine dendron (d) 
bis(hydroxymethyl)propionic acid
(f)Dendritic polyglycerol. 
                                  
Polymer dendrimer based on 2,2
(e) Dendrimers based on glycerol and succinic acid 
10 
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FIGURE 4.Transfection of DNA into the cell nucleus with the help of ‘activated’ dendrimers 
[32]. 
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Delivery of anticancer drugs through dendrimers     
Passive targeting of the drug into tumor site by these polymeric carriers has been possible 
because of the limited lymphatic drainage and increased permeability of tumor vasculature to 
macromolecules [43]. Both of these factors lead to the accumulation of macromolecules in tumor 
site in which the phenomenon termed as the enhanced permeation and retention (EPR) effect. 
Dendritic unimolecular micelles integrated with anticancer drugs such as methotrexate, 5-
fluorouracil has attained greater scope by addition of stabilizing PEO chains on the periphery of 
the dendrimers. Release of drugs can be controlled from encapsulated compartment of micelle by 
using hybrids of PEO and pH-sensitive hydrophobic acetal groups on the dendrimer 
periphery.Poly (glycerol and succinic acid) dendrimers for the delivery of group of anticancer 
drugs such as camptothecins were investigated. In a basic study by Griffin et al, G4-PGLSA 
dendrimers attached with carboxylate or hydroxyl peripheral groups were used to encapsulate 
10-hydroxycamptothecin for delivery to carcinogenic cells [44]. Because of the precipitation of 
G4-PGLSA-OH solution, relatively high water soluble G4- PGLSA-COONa polymeric 
dendrimer was used and 10-HPCT was favorably encapsulated and this has shown significant 
cytotoxicity with less than 5% of viable cells at 20µM when exposed to MCF-7 human breast 
cancer cells whereas the void dendrimer showed no cytotoxicity. A 3400 Da PEG core was 
inserted into the G4-PGLSA where 20 fold increase in water solubility of 10-HPCT was noted 
down following encapsulation and same cytotoxicity’s were observed for encapsulated and free 
10-HPCT when examined by HT-29 human colon cancer cells and hence, conclusions drawn 
from above two studies led to the selection of G4- PGLSA-COONa polymeric dendrimer as a 
drug carrier for 7-butyl-10-aminocamptothecin (BACPT) [45] and 10-HPCT.  
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Investigations were carried out for the anticancer activity on a human cancer cell line 
panel including MCF-7 breast carcinoma, HT-29 colon cancer, SF-268 astrocytoma and NCI-
H460 large cell lung carcinoma. Cellular uptake, cellular retention and solubility studies were 
also done for MCF-7 cells.10-HCPTencapsulated G4-PGLSA-COONa showed entire release of 
the drug within nearly 6 hours, indicating that the delivery system is more efficient when 
administered via intratumoral injection. Delivery of BACPT and 10-HCPT aided by dendrimer 
resulted in lowered IC50s for all cell lines tested (Fig. 5); When compared to free 10- HCPT 
dissolved in DMSO the encapsulated 10-HCPT exposed to HT-29,MCF-7, NCI-H460, and SF-
268 cells, IC50s were surprisingly reduced by 3.5, 7.1, 1.9, and 2.8-fold respectively. Exposure 
of BACPT to the successive cell lines above led to IC50 reductions of 1.2, 3.2, 1.9, and 5.7-fold 
respectively. Uptake studies proved that 10-HCPT encapsulated dendrimer was localized much 
faster than free 10-HCPT, with 8-fold intracellular concentrations at 10 h and 16-fold 
intracellular concentrations at 2 h and also longer retention time in the cell was showed by drug 
delivered through the dendrimers, with 50% of delivered 10-HCPT available in the cell after 30 
min, in comparison to 35% of free drug. Hence, an improved uptake and retention was observed 
because of the increased toxicity of delivered camptothecins. 
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FIGURE 5.Dendrimer aided drug delivery based on succinic acid and glycerol. Left, chemical 
structure of G4-PGLSA-COONa.Right,chemical structures of  (1)10-hydroxycamptothecin and 
(2)7-butyl-10-aminocamptothecin with IC50 values for HT-29 colorectal adenocarcinoma, MCF-
breast carcinoma,NCI-H460 large cell lung carcinoma, and SF-268 astrocytoma human cancer 
cell lines[45]. 
Some of the anticancer drugs like etoposide and doxorubicin were also encapsulated 
within the micelles where etoposide which is more lipophilic attained a loading capacity of 
approximately 22% compared to doxorubicin. Etoposide encapsulated dendrimer showed 
equivalent toxicity to free etoposide at identical concentrations of the drug whereas the unloaded 
one was non-cytotoxic to epithelial cells of porcine kidney. Paclitaxel, a mitotic inhibitor used in 
cancer chemotherapy achieved improved water solubility (ranging from 80-128µg/mL with 
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increasing generations from G3-G5) with polyglycerol dendrimer proving that a hydrophobic 
core is not so essential for solubilization and encapsulation of non-polar drugs [46]. 
Improved solubility and increased toxicity (lower IC50) of hydrophobic anti-cancer drugs 
through non-covalent encapsulation was shown by medium-generation dendrimers (G4–
G6).Therapeutic agents are localized within the inner core space or by micellar arrangement of 
the dendrimers. These delivery systems are more efficient when administered via intratumoral 
injection because they are deprived of controlled release pharmacokinetics when compared to 
most of the other systems releasing their payload over several hours. Reduced drug toxicity and 
enhanced solubility have been shown when melamine-based dendrimers were used with the 
anticancer drugs such as methotrexate and 6-mercaptopurine [47].Sub chronic doses of drug-
encapsulated dendrimers were given to C3H mice and ALT levels were tested to determine 
hepatotoxicity. ALT levels were reduced by 36% for the 6-mercaptopurine dendrimers and by 
27% for methotrexate-encapsulated dendrimers compared to same C3H mice treated with drug 
alone. 
Dendrimer drug conjugates 
Another way to the development of dendrimers as anti-neoplastic agents is to take 
advantage of their well-defined multivalency for covalent attachment to the peripheral groups of 
the dendrimer. It offers various advantages over encapsulated drug dendrimers. Multiple drug 
molecules can be attached to any of the dendrimer and drug release can be controlled by 
introducing degradable linkages between the dendrimer and drug. Payload of the drug can also 
be turned by changing the generation number of the dendrimer.  
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Kannan et al reported the synthesis of PAMAM-methotrexate conjugates from amine-
terminated G3 PAMAM or carboxylic acid-terminated G2.5 PAMAM in order to check the 
activity of dendrimer-delivered methotrexate to sensitive and resistant CCRF-CEM human acute 
lymphoblastoid leukemia and CHO (Chinese hamster ovary cell lines) [48]. Amine-conjugated 
G3PAMAM showed no increased sensitivity compared to free methotrexate while carboxylic 
acid-conjugated G2.5 PAMAM system showed increase in sensitivities of 8- and 24-fold for 
MTX-resistant cell lines CEM/MTX and RII despite both polymers were conjugated to the drug 
by the formation of amide bonds. Charge of the dendrimer carrier after cleavage of methotrexate 
from the peripheral groups was the main reason for differences in cytotoxicity. Decrease in 
lysosomal residence time for the cationic PAMAM is caused by the lysosomotropic effect, in 
which the dislocation of small basic molecules from the lysosome by positively-charged 
dendrimers is associated by an increase in pH and overall lysosomal disruption. As a result, the 
conjugates experience reduced interactions with proteases and diminished drug release indicating 
higher probability of dendrimer-drug conjugates for the treatment of carcinomas importantly 
those that have manifested immunity to chemotherapeutics.  
Frechet and Szoka reported an another remarkable dendritic drug delivery where an 
asymmetric doxorubicin-functionalized bow-tie dendrimer was produced by PEGylation of one 
side of a third generation 2,2-bis(hydroxymethyl)propionic acid dendrimer and attachment of the 
drug through an acyl hydrazone linkage to the other side (G4)resulting in a total of 8–10 wt.% 
doxorubicin [49] (Fig.6). A pH sensitive linkage has been used in between the drug and 
dendrimer to release the drug promptly in the cell. Tumor uptake was nearly 9-fold higher 
compared to free doxorubicin when intravenous injection to BALB/c mice with sub cutaneous C-
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26 colon carcinoma tumors was given. No cures were observed with drug alone treatments 
whereas a single injection of the drug dendrimer conjugate of doxorubicin caused complete 
tumor recession and 100% survival of mice in a period of two months. 
An interesting research has been carried out by Duncan et al. who have prepared 
conjugates of PAMAM dendrimers with cisplatin [50,51], a potent anticancer drug which is used 
to treat several types of cancers including sarcomas, some carcinomas, lymphomas, and 
particularly testicular cancer. But the main problem is they have poor aqueous solubility and 
nonspecific toxicity. The dendrimer platinum complex show decreased systemic toxicity, 
increased solubility and selective accumulation in solid tumors and has also been found to show 
increased ability relative to cisplatin in the treatment of B16F10 melanoma. 
 
Fig.6.Doxorubicin conjugated dendrimer.PEGylated polyester dendrimer with altering molecular 
weight, pharmacokinetics, aqueous solubility, biodistribution and drug-loading [49]. 
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Aliphatic polyester dendrimers on 2, 2-bis (hydroxymethyl) propionic acid are promising 
dendrimer backbones for the advancement of anticancer drug conjugates. In initial studies, a 
water-soluble polyester dendrimer was found to be biocompatible in vitro and in vivo [52]. 
Biodistribution studies in mice showed that the fourth-generation dendrimer with a molecular 
weight of 3800 had a circulation half-life of less than 10 min and was rapidly excreted in the 
urine. Although the observed lack of accumulation of the dendrimer in vital organs is a desirable 
feature for many biological applications, a longer half-life is required to obtain passive tumor 
targeting via the EPR effect. 
In other study, hybrids of polyester dendrimers and PEO star polymers (Fig.7a) [53] have 
been synthesized with an increase in molecular weight to 22,000. Hybrids with similar 
polydispersity are given by PEO since it is highly biocompatible [54] and available in low 
polydispersity (polydispersity index of 1.02). In addition to supplying a multivalent backbone for 
adherence of the drug, dendrimers also provide path to various new polymer architectures that 
are potentially relevant to drug delivery applications and one good example is ‘Bow-tie’ hybrids 
[55] of polyester dendrimers and PEO which were prepared by Gillies and Frechet group (Figure 
7b) with various molecular weights and architectures by modifying the number of PEO arms and 
their molecular weights.  
Biodistribution studies in vivo show that these new carriers with a molecular weight of 
more than 40,000 are generally long circulating with half-lives greater than 24 h, biodegradable 
and nontoxic in vitro. These highly branched carriers are excreted at a slower rate into the urine  
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by glomerular filtration, presumably as a consequence of their decreased flexibility and ability to 
axially diffuse through pores relative to linear polymers. Significant levels of the high molecular  
weight, long circulating bow-tie polymers is incorporated in subcutaneous B16F10 solid tumors 
via the EPR effect, making these new carriers, promising candidates for chemotherapeutic 
applications. 
Lately, some advances made in polymer and dendrimer chemistry have also provided 
access to a new class of macromolecules termed ‘dendronized polymers’ that is, linear polymers 
that bear dendrons at each repeat unit. Extended rigidified conformations of dendronized 
polymers are attained as a result of steric interactions, at high-generation numbers. Grayson, 
Fréchet and Lee et al. [56] have prepared polyester dendronized polymers having polyester 
dendrons based on backbones ranging from nondegradable poly (4-hydroxy) styrene to 
biodegradable polymers such as substituted polycaprolactone (Figure 7c) .As a result of their 
solubilizing groups, long circulation half-lives, numerous peripheral groups for the attachment of 
drugs and targeting moieties these polymers also show an assurance for drug delivery 
applications.  
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Figure 7.Linear polymer ‘bow-tie’ hybrids (a) Hybrid of polyester dendrons and PEO star [53] 
(b) ‘Bow-tie’ hybrid of PEO and polyester dendrimers [55] (c) Polyster dendronized linear 
polymer [56]. 
Boron neutron capture therapy 
Boron neutron capture therapy (BNCT) involves a lethal 10B (n, α) 7Li capture reaction 
that occurs when 10B is irradiated with low-energy thermal neutrons to yield high energy α-
particles and 7Li nuclei. These particles have limited path lengths in tissue (<10 µm) and thus 
their toxicity is limited to cells that have internalized 10B [57]. The use of BNCT as an important 
clinical treatment modality has been limited by either a lack of enough of tumor targeting or sub 
therapeutic 10B accumulation in cancer tissues. So in order to achieve tumor targeting in case of 
BNCT, macromolecular delivery vehicles have been prepared to enhance both the quantity and 
targeting of 10B to tumor cells by conjugating boron-containing complexes to monoclonal 
antibodies [58].  
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Human gliomas have been targeted with boronated G5-PAMAM conjugated to anti-EGF 
receptor monoclonal antibodies, which work against overexpressed tumor cell receptors. 
Boronated dendrimer was delivered through intratumorally or convection enhanced delivery 
(CED), a positive pressure method that facilitates transport across the blood–brain barrier, 
resulting in high retention of boron in the gliomas, with nearly 50% more accumulation resulting 
from the CED method. In following studies, boronated PAMAM dendrimers were designed to 
target the epidermal growth factor (EGF) receptor, a surface receptor that is most commonly 
overexpressed in brain tumors [59]. Accumulation of boron in cell lysosomes takes place 
because the dendrimers were covalently attached to EGF and the resulting conjugates were found 
to be actively endocytosed in vitro. PEO chain and fluorescent dansyl group can also be 
conjugated to the linker for water solubility and spectroscopic monitoring respectively. However, 
a full biological evaluation of these systems has not yet been investigated. 
Photodynamic therapy 
Photodynamic therapy is based on the activation of a photosensitizing agent with visible 
or near-infrared (NIR) light. Upon excitation, a highly energetic state is formed which on 
reaction with oxygen yields a highly reactive singlet oxygen, leading to cell death in tumor 
region [60]. PDT has been shown to reduce tumors by destruction of tumor neovasculature, 
direct cell killing, and initiating an acute inflammatory response that attracts leukocytes to the 
tumor .Various studies have inquired into the use of dendrons and dendrimers composed in part 
of multiple 5-aminolaevulinic acid (ALA) for enhanced intracellular accumulation of porphyrins 
and improved delivery . Conversion of protoporphyrin IX (PpIX) a photosensitizer, which 
specifically gets localized in tumors [61], is caused by ALA which is formed during the first step 
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of the heme biosynthetic pathway. Di Venosa et al. reported the synthesis of a G0-ALA dendron 
with a free amine at the core and three ALA groups at the periphery [62]. Equimolar equivalents 
of dendron to free ALA showed similar efficacy inducing porphyrin generation upon exposure to 
LM3 murine mammary adenocarcinoma cells. It was noted that only one of three ALA 
molecules was cleaved from the dendron within the cells. In comparison to largely researched 
lipophilic hexyl ester derivative of ALA (He-ALA), G0-ALA dendrons resulted in high 
accumulations of porphyrin in vivo both through topical and systemic deliveries.  
Dendritic molecules with up to 18 ALA moieties conjugated to the periphery by ester 
linkages that can be hydrolyzed in cellular conditions were reported by Edwards et al [63]. This 
delivery vehicle has been shown to result in higher toxicity after irradiation and increased 
production of PIX relative to free ALA. Lately, Fréchet and group [64] have used the multivalent 
aspect of the dendrimer surface to conjugate many two-photon absorbing chromophores to a 
porphyrin core. This system has been shown to generate singlet oxygen very effectively on 
irradiation at 780 nm. Recent studies are focused on the attachment of several solubilizing 
groups to the dendrimer periphery by preparing a water-soluble system. 
Photo thermal therapy 
This kind of therapy which involves minimally invasive tumor techniques[65-
68].Nanoparticles consisting of gold atoms have been developed that strongly absorb light in the 
near-infrared region, assisting in deep optical penetration into tissues, generating a limited and 
toxic dose of heat at the site of a tumor [69]. Methods for preparing metal-encapsulated 
dendrimers for use in biomedical applications were reported within the last ten years with the 
aim of adding a finer degree of control for tuning the biological interactions shown by the metal 
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particles, including use as biomarkers and contrast agents with the ease of surface modification, 
improved biocompatibility, retention, and for photothermal therapy. 
As reported by the Baker group fluorescein and folic acid were covalently conjugated to 
already synthesized NH2-terminated G5-PAMAMdendrimer-entrapped gold nano-particles for 
targeted delivery to tumor cells overexpressing folic acid receptors [70].The capacity of 
dendrimers to specifically bind to KB cells is shown in vitro and were internalized into 
lysosomes within 2 h.  The applicability of these particles for targeted hyperthermia treatment  
and as electron-dense contrast agents was identified and further studies on in vivo performance 
are currently being conducted. Some of the work is pending in the study to extend the absorption 
spectra to the IR region. 
Imaging 
The important purpose served by imaging in oncology is to diagnose, locate, stage, plan 
treatment, and potentially find recurrence. Magnetic resonance imaging (MRI) and Computed 
tomography (CT) are two methods of imaging associated with cancer diagnoses. For visualizing 
both tumor vasculature and lymphatic involvement Gd-labeled PAMAM systems have been 
used. G8-Gd-PAMAM contrast agents play an important role in aiding to notice changes in 
tumor permeability after a single large dose of radiation treatment through MRI [71]. An 
advantage of using fluorescent probes for tumor detection is improved biocompatibility 
compared to other types of contrast agents, but is affected from the poor penetration of light 
through tissue. Thomas et al. prepared G5-PAMAM dendrimers conjugated to folic acid and a 
fluorescent probe (6-TAMRA, 6T) to provide a minimally invasive solution to this obstacle, 
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which were consequently targeted to tumors in vivo and observed by a two-photon optical 
probe[72]. 
Nonpharmaceutical Applications of dendrimers 
Dendrimers have also been used as solubilizing agents in nonpharmaceutical areas apart 
from employment in the pharmaceutical field. Neofotistou et al. [73] used dendrimer as a 
solubilizing agent in a desalination system. In this study, they found that the scaling was totally 
inhibited scale deposition with the use of starburst NH2-PAMAM dendrimers (generation0.5, 1, 
1.5, 2, and 2.5).Ogava et al. studied the potential of water-soluble dendrimers as a potential 
fluorescent detergent to form micelles at very low CMC. The self-assembly of pyrene-cored poly 
(aryl ether) dendrimers have been studied, and it was shown that poly (aryl ether) dendrimers act 
as surfactant, which aggregate at quite low concentration in aqueous solution (1.8 - 10-5 M) to 
form micelles which was different from CMC of common detergents [74]. Cooper et al. 
synthesized DABdendr-(NH2)32, functionalized with a CO2-philic shell derived from a heptamer 
acid fluoride of hexafluoro propylene oxide, (CF3 CF2 CF2 (OCF (CF3) CF2)5 which was a fourth 
generation hydrophilic dendrimer. These dendritic surfactants were able to distillate methyl 
orange (a CO2 insoluble dye and a hydrophilic compound) from a solution of liquid carbon 
dioxide [75]. 
Conclusion 
Today many of the pharmaceutical companies and large number of patents focused on 
development of dendrimers for several therapeutic applications. Practical solutions to drug 
solubility issues, biodistribution and targeting were possible through these novel systems. Many 
studies have demonstrated that architecturally designed dendrimer can be modified for 
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bioavailability, biocompatibility, pharmacokinetics and targeted drug delivery to treat 
malignancies. Recent researches lead to the successes in simplifying and optimizing the 
preparation of dendrimers such as the ‘click’ and ‘lego’ approaches [76, 77], provide immense 
variety of structures and at the same time reducing the cost of their production. Areas that require 
continued research is the biodistribution behavior of dendrimers and the effect of peripheral 
dendritic groups on tissue localization. 
Some of the ongoing developments include the release of drug from dendrimer because 
of the huge globular architecture thus making difficult the engineering techniques involved in 
enzymatic cleavable linkages [78-80] and the other one is development of drug dendrimer 
conjugates as anti-cancer agents in order to ease administration and improve safety for patients 
by Starpharma [81]. Finally, from many of the research studies done on dendrimers it can be 
concluded that these multifunctional nanoparticulate systems are promising scaffolds for drug 
delivery with their various applications in targeting, imaging, diagnostics and therapy. 
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